RecruitingPhase 2NCT07080567

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

Sponsor

Emmanuel Carrera

Enrollment

80 participants

Start Date

Jul 14, 2025

Study Type

INTERVENTIONAL

Conditions

Stroke Ischemic Stroke Stroke, Acute

Summary

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mannitol and a drug called Maraviroc for people with ischemic stroke, stroke, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.